RecruitingPhase 2NCT02728388
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Studying Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Donald Basel
- Principal Investigator
- Donald G Basel, MDMedical College of Wisconsin
- Intervention
- aminolevulinic acid(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 14-30 years · All sexes
- Timeline
- 2016 – 2025
Study locations (1)
- Donald G Basel, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02728388 on ClinicalTrials.govOther trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07407803Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGNANCT07233408Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health LiteracyMassachusetts General Hospital
- RECRUITINGPHASE2NCT06188741Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1University of Alabama at Birmingham
- RECRUITINGNANCT06360406Real-World Treatment Study of Koselugo (Selumetinib)AstraZeneca
- RECRUITINGPHASE1, PHASE2NCT06159166Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).Johns Hopkins University
- RECRUITINGPHASE1NCT06104488A Study of Avutometinib for People With Solid Tumor CancersMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05521048Doxycycline in Cutaneous Schwannoma (NF2)Massachusetts Eye and Ear Infirmary
- ACTIVE NOT RECRUITINGNANCT03873610Resiliency Training in Adolescents With NF1 and NF2Massachusetts General Hospital
See all trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →